BRD2 upregulation as a pan-cancer adaptive resistance mechanism to BET inhibition
Abstract Bromodomain and extraterminal motif (BET) inhibitors, such as JQ1, are promising cancer therapeutics that target epigenetic regulators, particularly BRD4. However, resistance to BET inhibitors (BETi) limits their clinical utility, necessitating a better understanding of adaptive mechanisms....
Uloženo v:
| Hlavní autoři: | , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BMC
2026-05-01
|
| Edice: | Cellular & Molecular Biology Letters |
| Témata: | |
| On-line přístup: | https://doi.org/10.1186/s11658-026-00922-y |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|